Cytokinetics, Incorporated
CYTK
$38.34
$0.290.76%
NASDAQ
06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
---|---|---|---|---|---|
Revenue | 2,635.74% | 412.21% | 145.34% | -58.81% | -68.51% |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | 2,635.74% | 412.21% | 145.34% | -58.81% | -68.51% |
Cost of Revenue | 18.85% | 7.65% | 2.81% | 3.31% | 9.42% |
Gross Profit | 6.34% | -3.03% | 0.51% | -4.86% | -12.10% |
SG&A Expenses | 34.08% | 34.07% | 24.02% | 7.43% | -5.76% |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 24.25% | 16.57% | 10.12% | 4.81% | 3.51% |
Operating Income | -8.08% | -13.59% | -8.07% | -5.81% | -5.00% |
Income Before Tax | -11.19% | -15.96% | -12.03% | -9.43% | -1.05% |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -11.19% | -15.96% | -12.03% | -9.43% | -1.05% |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -11.19% | -15.96% | -12.03% | -9.43% | -1.05% |
EBIT | -8.08% | -13.59% | -8.07% | -5.81% | -5.00% |
EBITDA | -9.01% | -14.53% | -8.76% | -4.61% | -3.78% |
EPS Basic | 4.66% | 1.75% | 3.20% | 2.39% | 5.62% |
Normalized Basic EPS | 4.66% | 1.75% | 3.20% | 2.40% | 1.52% |
EPS Diluted | 4.66% | 1.75% | 3.20% | 2.39% | 5.62% |
Normalized Diluted EPS | 4.66% | 1.75% | 3.20% | 2.40% | 1.52% |
Average Basic Shares Outstanding | 16.59% | 17.99% | 15.77% | 12.12% | 7.10% |
Average Diluted Shares Outstanding | 16.59% | 17.99% | 15.77% | 12.12% | 7.10% |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |